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Abstract
Background: Cholesterol oxidase is an alcohol dehydrogenase/oxidase flavoprotein that catalyzes the 
dehydrogenation of C(3)-OH of cholesterol. It has two major biotechnological applications, i.e. in the determination of 
serum (and food) cholesterol levels and as biocatalyst providing valuable intermediates for industrial steroid drug 
production. Cholesterol oxidases of type I are those containing the FAD cofactor tightly but not covalently bound to 
the protein moiety, whereas type II members contain covalently bound FAD. This is the first report on the over-
expression in Escherichia coli of type II cholesterol oxidase from Brevibacterium sterolicum (BCO).
Results: Design of the plasmid construct encoding the mature BCO, optimization of medium composition and 
identification of the best cultivation/induction conditions for growing and expressing the active protein in 
recombinant E. coli cells, concurred to achieve a valuable improvement: BCO volumetric productivity was increased 
from ~500 up to ~25000 U/L and its crude extract specific activity from 0.5 up to 7.0 U/mg protein. Interestingly, under 
optimal expression conditions, nearly 55% of the soluble recombinant BCO is produced as covalently FAD bound form, 
whereas the protein containing non-covalently bound FAD is preferentially accumulated in insoluble inclusion bodies.
Conclusions: Comparison of our results with those published on non-covalent (type I) COs expressed in recombinant 
form (either in E. coli or Streptomyces spp.), shows that the fully active type II BCO can be produced in E. coli at valuable 
expression levels. The improved over-production of the FAD-bound cholesterol oxidase will support its development 
as a novel biotool to be exploited in biotechnological applications.
Background
Cholesterol oxidase (EC 1.1.3.6, CO) is an alcohol dehy-
drogenase/oxidase flavoprotein that catalyzes the dehy-
drogenation of C(3)-OH of a cholestane system to yield
the corresponding carbonyl product. During the reduc-
tive half-reaction, the oxidized FAD cofactor accepts a
hydride from the substrate and in the ensuing oxidative
half-reaction, the reduced flavin transfers the redox
equivalents to molecular oxygen yielding hydrogen per-
oxide. Interestingly, CO also catalyzes the isomerization
of cholest-5-en-3-one (the product of the redox reaction)
to cholest-4-en-3-one.
CO is an useful biotechnological tool employed: i) for
the determination of serum (and food) cholesterol levels,
ii) as biocatalyst providing valuable intermediates for
industrial steroid drug production, iii) as larvicidal pro-
tein (the one from Streptomyces sp. strain A19249) that
has being developed as an insecticide against Coeloptera.
Furthermore, CO has been proposed as a virulence factor
playing a role in infections caused by the pathogen bacte-
rium Rhodococcus equi. Since this enzymatic activity is
unique to bacteria, it may represent a novel molecular
target for antibiotic discovery. CO also acts as signaling
protein for the biosynthesis of polyene macrolide pimari-
cin in Streptomyces natalensis. For a review see [1-4].
CO is produced, and frequently secreted, by a variety of
prokaryotic microorganisms. CO from Brevibacterium
sterolicum (BCO) is produced as a 613 amino acid long
precursor (full length BCO, fBCO) that lacks the N-ter-
minal pre-sequence (52 amino acid long) to yield the
mature and fully active enzyme form (Figure 1). BCO is
the prototype of type II COs: it contains a FAD cofactor
covalently bound to His69 and belongs to the family of
vanillyl-alcohol oxidase, whose members possess a fold
proposed to favour covalent flavinylation [5]. The mem-
bers of CO class type I (such as the one from Streptomy-
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ces hygroscopicus or Rhodococcus equi) contain the FAD
cofactor tightly but non-covalently bound to the protein
moiety. Enzymes belonging to these two classes show no
significant sequence identity, possess different tertiary
structure, and have different kinetics mechanism and
redox potentials [2,3]. In recent years, we elucidated the
f u n c t i o n  o f  c o v a l e n t  fl a v i n  l e a k a g e  s t u d y i n g  t h e  H 6 9 A
BCO mutant, in which the amino acid substitution pre-
vents formation of the histidyl-FAD bond. The mutant
BCO shows a similar structure compared to the wild-type
enzyme and retains catalytic activity (both the oxidation
and the isomerisation reaction) but with a 35-fold
decrease in turnover number, a 100 mV more negative
midpoint reduction potential, and a significant lower sta-
bility to denaturant agents and temperature than the
covalent counterpart [6-8]. We thus concluded that this
c o v a l e n t  b o n d  r e p r e s e n t s  a  s t r u c t u r a l  d e v i c e  t o  b o t h
modify the reduction potentials (catalytic power) of the
cofactor and to stabilize the tertiary structure.
BCO shows peculiar characteristics that makes it a suit-
able biotechnological tool, such as a higher apparent kcat
value on cholesterol as compared to non-covalent CO (2-
15 fold higher, depending on the experimental conditions
used) and a 5-fold lower Km,O2 [2,9]. Furthermore, the sta-
ble cofactor interaction makes BCO a better choice than
non-covalent COs for those applications where FAD dis-
sociation reduces the biocatalyst performances (e.g.,
immobilized-based processes and biosensors) [3]. In fact,
the apoprotein of S. hygroscopicus CO (type I-CO) is
highly unstable [2].
Despite its biotechnological importance, no detailed
analysis has been so far reported concerning the over-
production of type II-CO members (containing cova-
lently bound FAD) as recombinant proteins. Previous
results revealed that recombinant wild-type BCO (as well
as some of its point mutants) were produced as a mixture
of two enzyme forms containing covalently (flavinylated)
and non-covalently bound FAD, as judged by spectral and
kinetics analysis [10]. This is the first report of BCO over-
expressed in E. coli using different constructs and media,
and under cultivation/induction controlled conditions at
flask and fermentor scale. The aim of this work is to verify
the effect of these factors on the overall BCO production
as well as on its partitioning between the form containing
covalently-bound FAD (the fully active enzyme species)
and its non-covalent (marginally active) counterpart. The
promising results hereby reported, will favour the use of
this recombinant strain for future CO biotechnological
production.
Results
Expression of different BCO forms
Synthetic cDNAs encoding full length and mature BCO
forms (whose codon usage was optimized for E. coli
expression) were subcloned into pET24b(+) plasmid giv-
ing a 621 amino acid long protein (fBCO, of 67.51 kDa) or
a 578 amino acid long BCO (mBCO, of 63.59 kDa),
respectively, both containing a C-terminal His tag (Figure
1). The mBCO form also contains an additional 9-resi-
dues long N-terminal sequence, previously demonstrated
to be necessary for successful protein crystallization [2,8].
In preliminary experiments both the constructs were
used to express BCO in E. coli BL21(DE3)pLysS cells
grown in LB medium, by inducing the protein expression
with 1 mM IPTG at different times of growth and collect-
ing the cells (grown at 25 or 37°C) 3, 7 or 18 hours after
induction. As summarized in Table 1, the mBCO form
shows the highest expression of BCO activity. In the cases
of fBCO, the best expression conditions (260 U/L culture)
are obtained when IPTG is added during exponential
growth phase and cells are collected after a prolonged
(overnight) incubation at 25°C. In the same conditions, a
volumetric productivity of nearly 500 U/L culture of
mBCO with a specific activity of 0.54 U/mg protein is
Figure 1 Sequence alignment of the BCO forms expressed in E. coli. fBCO: Protein obtained by subcloning the fBCO-cDNA into pET24b(+) using 
the NdeI/XhoI restriction sites; mBCO: protein obtained by subcloning the mBCO-cDNA into pET24b(+) using the NdeI/XhoI restriction sites. For com-
parison, the sequence of the "mature" form of BCO (as determined from the 3-D structure, PDB code 1I19) is reported.Volontè et al. BMC Biotechnology 2010, 10:33
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obtained. When induction is performed in the stationary
phase at 25°C slightly lower expression levels of mBCO
(400 U/L culture) is achievable after three hours, indicat-
ing that a more rapid expression kinetics occurs in these
conditions.
SDS-PAGE Analysis of soluble and insoluble fractions
(pellet) after lyses of cells induced with 1 mM IPTG at an
OD600 nm~1, clearly indicates that at the post-induction
temperature of 37°C a large amount of the fBCO as well
as mBCO protein is produced in the insoluble fraction
(not shown). When cells are incubated at 25°C after the
induction, a significant amount of recombinant fBCO is
found in the insoluble fraction, whereas mBCO is
expressed to a large extent in the soluble form. Based on
these results, the subsequent investigations were focused
on the mBCO form.
Optimization of the mBCO production conditions
The expression of recombinant mBCO was then investi-
gated using a modified 2.6-kb-shorter version of pET24Δ
plasmid as expression vector (i.e., pET24Δ plasmid, see
Methods for details), that was previously reported to
increase protein expression yield [11]. In fact, the expres-
sion level in LB broth under experimental conditions sim-
ilar to those reported above (induction at the exponential
growth phase by 1 mM IPTG followed by overnight incu-
bation at 25°C) is about twice than that observed with the
longer plasmid: 860 U/L with a specific activity of 1.7 U/
mg protein are thus achieved (Table 2).
In order to optimize mBCO expression, several experi-
mental parameters were modified at flask-scale: cultiva-
tion medium composition, IPTG concentration, growth
phase at induction, and incubation temperature after
induction. The medium composition significantly affects
mBCO expression. Very low mBCO expression is
observed in M9 minimal medium (0.7 U/L and 0.003 U/
mg protein). As expected, richer media support higher
biomass production: more than 20 g cells/L are produced
in TB, in TB/glucose (a TB medium containing 5 g/L glu-
cose instead of glycerol) and SB media following over-
night growth after induction, in comparison to the 6-7 g/
L cells sustained by LB medium (Table 2). The medium
composition also appreciably affects the mBCO's volu-
metric productivity and specific activity in the crude
extract: these figures are significantly higher in richer
media with respect to LB. The presence of glycerol as car-
bon source (TB medium) seems to play a positive effect
on mBCO production (up to 13300 U/L culture, 5.9 U/
mg protein), whereas when it is replaced by glucose (TB/
glucose medium) the volumetric yield is halved (see
below and Table 2). SB medium sustains a more rapid
production of biomass (more than 20 g/L cells achieved
in 3 hours after IPTG addition) in comparison to TB, but
this is not accompanied by an increase in mBCO produc-
tivity, which did not exceed the 9500 U/L culture and the
2.1 U/mg protein. In all the tested media, mBCO produc-
tion is higher when the cells are collected 18 hours after
induction. The concentration of IPTG does not appear to
exert a significant effect either on cell growth or on pro-
tein expression: similar values of biomass and mBCO
expression are obtained at ≥ 0.25 mM inducer concentra-
tion (Table 2). This is a valuable result since IPTG repre-
sents the most expensive component used in E. coli
recombinant protein production.
I n  r i c h e r  m e d i a ,  s u c h  a s  T B  a n d  S B ,  i n d u c t i o n  o f
mBCO expression during mid-exponential phase (OD600
nm = 1.5-2) results in higher production than at early
exponential phase (OD600 nm = 0.8-1): more than 11000
vs. 6000 U/L culture with a specific activity of 3.9 vs. 2.8
U/mg protein are produced in TB following IPTG addi-
tion at and OD600 nm~2 and ~1, respectively, in compari-
son to 7800 vs. 4800 U/L culture and 4.0 vs. 2.4 U/mg
protein in SB medium. Reduced expression of mBCO is
indeed observed following addition of IPTG to cells
grown in TB from the late exponential phase (OD600
nm~6-7) till the advanced stationary phase (OD600 nm~9)
and collected after 24 hours (data not shown).
Concerning the impact of medium components, glyc-
erol appears to play a major role on mBCO expression,
whereas phosphate buffer seems to exert a minor effect.
Addition of glycerol to SB medium increases both the
specific and the volumetric productivity, whereas addi-
tion of phosphate salts does not (Table 3). A similar result
is observed in TB medium: removal of phosphate salts
does not negatively influence the biomass production or
the mBCO expression, whereas in the absence of glycerol
both these parameters are significantly reduced (Table 3).
Interestingly, glycerol addition to LB medium does not
change the volumetric productivity (Table 3). Indeed,
increasing the amount of glycerol in TB medium up to 20
mL/L generates an improvement in the volumetric pro-
ductivity as well as in the specific activity of mBCO, but it
does not seem to significantly affect cell growth (Table 3).
At 20 mL/L of glycerol, about 14000 U/L culture and 5.9
U/mg protein are produced. The temperature of incuba-
tion after IPTG addition is confirmed as a crucial factor
affecting mBCO expression: in the four different tested
media, the highest enzyme production is observed at
25°C and at 18°C, while incubation at 37°C results in a
dramatic activity decrease (Table 3) and at 42°C cell lysis
is observed. Under all conditions tested, no mBCO activ-
ity is detected in the cultivation medium.
Fermentor scaling up
The best conditions set up at flask level were scaled up at
2 L fermentor scale. Cell were grown at 37°C in TBVolontè et al. BMC Biotechnology 2010, 10:33
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medium added with 20 mL/L glycerol and IPTG-induced
during early-exponential phase (OD600 nm = 1.5-2). At the
time of induction, temperature was shifted to 21°C, and
the kinetics of BCO production in this condition was fol-
lowed for additional 24 hours (Figure 2). After a short lag
phase of one-two hours, the culture starts to grow expo-
nentially: 25 g cells/L are produced in 18-20 hours after
the inoculum. More than 25000 U/L culture and 7 U/mg
BCO are accumulated by cells entering into stationary
phase (18-20 hours). After 24 hours, protein production
starts to slowly decrease: comparison by means of West-
ern blot and activity assays (see below) of the amount of
expressed BCO indicates that the observed decrease is
mainly due to protein degradation (i.e. a similar decline in
terms of BCO production and enzyme activity is
observed). Indeed, the amount of BCO activity recovered
from fermentation broth is <2% of the intracellular enzy-
matic activity, confirming that the protein is not released
from the cells.
Production of covalent vs. non-covalent mBCO
All the above results are based on the measurement of the
enzymatic activity in the crude soluble extracts and thus
account only for the soluble and catalytically active (i.e.,
the one containing covalently bound FAD) mBCO. West-
ern-blot analysis of both soluble and insoluble fractions
obtained after cells disruption indicate that a significant
amount of mBCO is also present in the insoluble fraction
(data not shown). Anyway, these analyses do not clarify if
the expressed protein is produced or not as covalent fla-
voprotein. Hence, the relative abundance of the flaviny-
lated vs. the non-covalent mBCO form was assessed by
the spectral analysis of purified enzyme preparations (the
covalent BCO shows absorbance maxima at 368 and 448
nm, while those of the non-covalent BCO are at 389 and
444 nm, with a significant increase in the extinction coef-
ficient at this latter wavelength) and by activity assay (the
non-covalent BCO possesses a specific activity 35-fold
lower than the covalent one) [6]. In order to assess the
Table 1: Expression of the BCO forms using different growth and induction conditions.
Phase of induction Plasmid
(BCO form)
Time after 
induction
(h)
Temperature after induction
25°C 37°C
U/mgprotein U/Lculture U/mgprotein U/Lculture
Exponential phase (OD600 nm~1) pET-fBCO (fBCO) 0 b.d. b.d. b.d. b.d.
3 ≤ 0.01 < 1.0 ≤ 0.01 < 1.0
7 0.07 ± 0.005 2.0 ± 0.3 0.10 ± 0.05 < 1.0
18 0.16 ± 0.05 260 ± 80 0.12 ± 0.02 1.8 ± 0.2
pET-mBCO (mBCO) 0 b.d. b.d. b.d. b.d.
3 0.31 ± 0.02 130 ± 10 0.09 ± 0.02 50 ± 11
7 0.38 ± 0.14 190 ± 50 1.0 ± 0.3 390 ± 45
18 0.54 ± 0.15 500 ± 120 0.17 ± 0.06 240 ± 20
Stationary phase (OD600 nm~2) pET-fBCO (fBCO) 0 b.d. b.d. b.d. b.d.
3 ≤ 0.01 < 1.0 ≤ 0.01 < 1.0
7 ≤ 0.01 1.1 ± 0.1 ≤ 0.01 < 1.0
18 0.03 ± 0.015 2.5 ± 0.4 0.02 ± 0.01 1.8 ± 0.2
pET-mBCO (mBCO) 0 b.d. b.d. b.d. b.d.
3 0.52 ± 0.12 400 ± 10 0.22 ± 0.06 150 ± 35
7 0.28 ± 0.02 180 ± 20 0.55 ± 0.18 180 ± 10
18 0.13 ± 0.02 110 ± 30 0.12 ± 0.05 85 ± 9
In all cases, E. coli cells carrying the recombinant pET24b(+)-BCO plasmids were cultivated in LB medium and protein expression was induced by 
1 mM IPTG addition. b.d., below detection limit. Data are expressed as mean ± S.D., n = 3.Volontè et al. BMC Biotechnology 2010, 10:33
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effect of the cultivation/expression conditions on the fla-
vinylated vs. non-covalent mBCO ratio, we compared the
total expression level, as estimated on the basis of West-
ern-blot analysis, with the amount of the covalent form,
as determined analyzing flavin fluorescence of SDS-
PAGE unstained gels (mBCO form containing the cova-
lently-bound FAD does not lack the cofactor during the
electrophoretic separation and thus maintains flavin fluo-
rescence, Figure 3). Under all the tested expression condi-
tions (the ones reported in Tables 2 and 3), recombinant
mBCO is present in both the soluble and insoluble frac-
tion, but no flavin fluorescence is observed in the lanes
corresponding to the insoluble fractions. These results
indicate that when the expressed mBCO accomplishes
the folding and the flavinylation process, it becomes a sol-
uble protein, while the non-covalent mBCO remains (at
least partially) present as insoluble protein.
Table 2: Effect of medium composition, IPTG concentration and time of protein induction on mBCO expression.
Medium [IPTG]
(mM)
Time after 
induction
(h)
Biomass
(g/Lculture)
Specific activity
(U/mgprotein)
Volumetric 
productivity
(U/Lculture)
LB / 0 5.9 ± 0.3 < 0.01 0.5 ± 0.3
0.25 3 5.9 ± 0.8 1.5 ± 0.4 550 ± 100
18 7.3 ± 0.4 1.5 ± 0.2 890 ± 280
0.5 3 6.1 ± 0.5 1.4 ± 0.2 460 ± 170
18 5.9 ± 0.2 1.4 ± 0.4 700 ± 220
1 3 5.9 ± 0.8 1.5 ± 0.1 570 ± 160
18 6.8 ± 0.1 1.7 ± 0.6 860 ± 190
TB / 0 7.6 ± 0.9 ≤ 0.02 8.9 ± 2.3
0.25 3 10.8 ± 1.4 1.1 ± 0.2 830 ± 50
18 26.2 ± 3.9 5.9 ± 1.3 13300 ± 350
0.5 3 10.6 ± 1.4 1.0 ± 0.2 1000 ± 200
18 24.8 ± 4.0 3.3 ± 0.5 11400 ± 1800
1 3 10.3 ± 0.8 1.2 ± 0.1 940 ± 50
18 24.3 ± 2.3 3.9 ± 0.1 11100 ± 1700
TB/
glucose
/ 0 8.5 ± 1 ≤ 0.02 3.6 ± 1.3
0.25 3 14.9 ± 1.9 3.2 ± 0.6 1260 ± 80
18 21.0 ± 3.1 3.1 ± 0.7 5440 ± 140
0.5 3 15.9 ± 2.1 2.3 ± 0.5 1220 ± 240
18 20.0 ± 3.2 5.1 ± 0.8 6400 ± 900
1 3 17.4 ± 1.4 2.4 ± 0.2 1340 ± 70
18 20.4 ± 1.9 5.3 ± 0.1 6300 ± 900
SB / 0 11.4 ± 1.3 ≤ 0.01 15 ± 8
0.25 3 20.2 ± 2.6 3.3 ± 0.7 4050 ± 240
18 16.0 ± 2.4 3.2 ± 0.7 8200 ± 220
0.5 3 22.0 ± 2.4 1.3 ± 0.7 3160 ± 690
18 23.2 ± 0.8 2.1 ± 0.3 9500 ± 2100
1 3 18.9 ± 2.4 1.8 ± 0.4 2520 ± 150
18 18.8 ± 2.8 4.1 ± 0.9 7900 ± 210
E. coli cells carrying the recombinant pET24 -mBCO plasmid were grown at 37°C until OD600 nm~1.5-2, added of IPTG, incubated at 25°C and 
harvested after 3 or 18 hour from the protein induction. Data are expressed as mean ± S.D., n = 3.Volontè et al. BMC Biotechnology 2010, 10:33
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With the aim of understanding the effect of the growth
conditions on the flavinylated vs.  non-covalent mBCO
ratio in the soluble protein fraction, the expressed
enzyme was purified from the crude extracts by Ni2+-
affinity chromatography. The highest amount of total sol-
uble mBCO is obtained using TB (with or without addi-
tional glycerol) at 18°C (Figure 4, top panel), with a
significant increase (about 7-fold) compared to standard
conditions (LB medium at 25°C). The percentage of cova-
lent mBCO in respect to the total amount of the pro-
duced soluble protein (as estimated by heat denaturation,
see Methods) is also higher under these experimental
conditions, but it never exceeds the 55% of the soluble
mBCO (Figure 4, bottom panel).
Discussion
Many proteins in nature necessitate the binding of spe-
cific cofactors to perform their biological function. These
Table 3: Effect of glycerol, phosphate and incubation temperature after IPTG addition on mBCO expression.
Medium Temperature after 
induction
(°C)
Biomass
(g/Lculture)
Specific activity
(U/mgprotein)
Volumetric 
productivity
(U/Lculture)
LB 18 8.7 ± 1.9 1.3 ± 0.3 770 ± 130
25 6.8 ± 0.7 1.7 ± 0.3 860 ± 80
37 5.3 ± 0.5 ≤ 0.01 3.0 ± 0.3
LB+G 25 12.7 ± 1.3 0.87 ± 0.10 760 ± 80
37 10.8 ± 1.1 0.08 ± 0.01 65 ± 7
TB 18 18.7 ± 3.3 3.8 ± 0.6 8030 ± 1400
25 24.3 ± 2.6 3.9 ± 1.0 11100 ± 1100
37 22.7 ± 2.4 ≤ 0.01 9.0 ± 0.9
TB-Pi 25 28.3 ± 3.1 4.1 ± 1.1 13100 ± 1300
TB-G 25 18.0 ± 1.0 3.0 ± 0.5 6140 ± 200
37 6.0 ± 0.3 ≤ 0.01 7.0 ± 0.2
TB+4G 25 22.4 ± 2.5 2.8 ± 0.5 11000 ± 400
TB+G 25 24.3 ± 2.6 3.9 ± 0.9 11200 ± 1100
TB+20G 25 21.9 ± 1.5 5.9 ± 1.0 14200 ± 2800
TB-Pi-G 25 19.8 ± 1.1 2.8 ± 0.5 8000 ± 260
SB 25 18.8 ± 0.7 4.1 ± 0.2 7900 ± 140
SB+Pi 25 19.5 ± 1.4 3.5 ± 1.1 8720 ± 2340
SB+G 25 22.5 ± 1.6 4.6 ± 0.8 11100 ± 1500
SB+G+Pi 25 19.2 ± 1.3 5 ± 1 10300 ± 1700
E. coli cells carrying the recombinant pET24 -mBCO plasmid were grown at 37°C, BCO expression was induced by 1 mM IPTG at OD600 nm = 
1.5-2 and harvested after 18 hours at different temperatures. G: glycerol. +G, +Pi: media added of glycerol (8 mL/L) and/or phosphate salts 
(70 mM), respectively; +4G and +20G: media added of 4 mL/L and 20 mL/L glycerol, respectively; -G, -Pi: media deprived of glycerol and/or 
phosphate salts, respectively. Data are expressed as mean ± S.D., n = 3.Volontè et al. BMC Biotechnology 2010, 10:33
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molecules often fold in vivo in cellular environments
where their cognate cofactors are available, and thus may
bind to the appropriate polypeptide before folding. It is
generally assumed that cofactors serve as nucleation sites
that drive or facilitate the overall folding process since
that the search of an unfolded polypeptide for the native
state is made easier due to the cofactor's coordination. A
number of investigations suggest a post-translational
rather than a co-translational process of flavinylation
[12]. In this study we investigated the over-expression of a
type II-CO from the high G-C gram-positive Brevibacte-
rium sterolicum, which is a flavoprotein containing cova-
lently-bound FAD, in the gram-negative E. coli as
heterologous host. Published results [13-25] only focused
on non-covalent (type I) COs expressed in recombinant
form either in E. coli or Streptomyces spp. (see Additional
file 1 - Heterologous expression of cholesterol oxidases).
Most of them are produced in nature by high G-C gram-
positives such as Streptomyces,  Rhodococcus  and
Brevibacterium spp., except those originating from Burk-
holderia  and  Chromobacterium  spp. It cannot be
excluded that recombinant production of the covalent
BCO in E. coli may be limited since the folding procedure
proceeds in a cellular environment different from that of
the natural producer. Nevertheless, optimization of plas-
mid construct (the one encoding for mature BCO),
medium composition (TB added of 20 mL/L of glycerol),
growth temperature after induction (21°C) and harvest
time (16-18 hours after induction), allowed to increase
the amount of mBCO activity expressed in E. coli from
~500 up to more that 25000 U/L culture at 2 L fermentor
scale and from 0.5 up to more than 7.0 U/mg protein in
the crude extract. This expression level compared favour-
ably with previous trials (see Additional file 1 - Heterolo-
gous expression of cholesterol oxidases) of non-covalent
(type I) COs. Only the expression of Rhodococcus equi
CO in Streptomyces lividans yielded a slightly higher vol-
umetric productivity, although its production time was 5-
fold longer [13]. Similarly, longer times were required to
obtain a higher specific activity in the crude extract for
Streptomyces spp. (ChoA gene) CO in E. coli JM109 [14]
(see Additional file 1 - Heterologous expression of choles-
terol oxidases).
W e  a l s o  d e m o n s t r a t e d  t h a t  w h e n  m B C O  i s  o v e r -
expressed in E. coli, the flavinylated enzyme form is fully
soluble, whereas the non-covalently FAD bound mBCO
largely accumulates in insoluble inclusion bodies. The
s o l u b l e  f r a c t i o n  i s  i n d e e d  a  m i x t u r e  o f  c o v a l e n t  ( f u l l y
active) and non-covalent mBCO forms: under optimal
expression conditions, nearly 55% of the soluble recombi-
nant mBCO is produced as covalently FAD bound form.
From the soluble fraction, a >95% homogeneous prepara-
tion of flavinylated mBCO can be easily recovered due to
the higher thermostability of the covalent form [10]: for
example, 3 min of incubation at 45°C in the presence of
0.5 mM cholesterol yields a complete denaturation of the
non-covalent form, while the flavinylated mBCO is fully
stable. Interestingly, the percentage of covalent mBCO in
the soluble crude extract is lower using conditions at
which the overall mBCO production is reduced (e.g., in
LB medium, see Table 3 and Figure 3), indicating that its
production may be not limited by saturation of protein
folding machinery or by coenzyme depletion.
Conclusions
Fully active type II mBCO has been produced in E. coli at
expression levels comparable with the best ones previ-
ously achieved for the biotechnological production of
non-covalent (type I) COs (see Additional file 1 - Heterol-
ogous expression of cholesterol oxidases). Under these
conditions, inclusion bodies contain the insoluble non-
covalently bound mBCO, whereas the soluble fraction is a
mixture of both the covalently and the non-covalently
bound FAD mBCO forms. From the soluble fraction, the
flavinylated enzyme can be easily recovered due to its
higher thermostability in comparison to the non-cova-
lently bound FAD mBCO form. Taking all together these
results, we conclude that the optimization of mBCO
over-expression in E. coli allows to produce huge
amounts of the (fully active) CO containing covalently
Figure 2 Production of mBCO in 2 L-batch fermentation of re-
combinant E. coli cells under optimized conditions. Top panel: time 
course of pH (down triangle), pO2 (up triangle), temperature (square), 
and growth curve measured as OD600 nm (circle). Bottom panel: produc-
tion of mBCO measured as specific activity (U/mg, filled bars) and vol-
umetric productivity (U/L, empty bars). The arrow indicates the 
moment of IPTG addition.Volontè et al. BMC Biotechnology 2010, 10:33
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bound FAD as a novel biotool to be preferentially used in
those biotechnological applications (e.g., immobilized
enzyme based-process and/or in flow biosensors) where
FAD dissociation from type I cholesterol oxidases may
reduce the biocatalyst efficiency.
Methods
Design, synthesis and cloning of cDNA encoding for 
different BCO forms
The synthetic cDNA encoding for the mature BCO
(mBCO) was designed based on the amino acid sequence
reported in the protein 3-D structure (PDB code 1I19)
[5], with an additional 9-amino acid N-terminal tag
(MSNHHHGHA), which is also present in the commer-
cial BCO (S. Ghisla, personal communication). This addi-
tional sequence is not very effective as protein
purification tag (the purification yield of commercial
BCO on HiTrap chelating column never exceeded 50%)
while it appears to play an important role in crystals
growth (a successful crystallization of wild-type and
mutants of BCO was never achieved using a protein lack-
ing this N-terminal sequence) [2,8]. The full length BCO
(fBCO) contains a 52-residue long N-terminal pre-
sequence according to the sequence GI:116363, locus
P22637 corresponding to the Brevibacterium sterolicum
CO protein. Notably, the sequence of the original gene is
unknown. Both the synthetic cDNA molecules (named
mBCO- and fBCO-cDNA, respectively) were synthesized
by Medigenomix GmbH (Martinsried, Germany), follow-
ing optimization of the coding nucleotide sequence for
expression in E. coli. Both the cDNA molecules were
cloned into pET24b(+) expression plasmid (Novagen)
using the NdeI/XhoI restriction sites. The mBCO encod-
ing cDNA was also inserted into a 2.6-kb-shorter version
of the pET24b(+) plasmid, obtained by a BglII/Tth111I
double digestion followed by treatment with Klenow
e n z y m e  a n d  l i g a t i o n  ( n a m e d  p E T 2 4 Δ  p l a s m i d )  [ 1 1 ] .
Because of the small size, this plasmid was previously
demonstrated to increase the transformation and the
Figure 3 Determination of the flavinylated vs. non-covalent re-
combinant mBCO by means of SDS-PAGE analysis. SDS-PAGE Gel 
was analyzed for flavin fluorescence (panel A) and subsequently 
stained for total proteins with Coomassie-blue (panel B). Conditions: 
recombinant E. coli cells grown in LB medium, added of 1 mM IPTG at 
OD600 nm = 0.9, then incubated at 25°C and collected after 18 hours. I, 
Insoluble fraction (pellet after cell disruption and centrifugation); S, sol-
uble fraction (soluble crude extract). An amount of sample corre-
sponding to 0.1 mL of fermentation broth was loaded in each lane. 
BCOcov and BCOncov: purified flavinylated and non-covalent mBCO 
forms, respectively; the amount of enzyme loaded are indicate in mi-
crograms. M: molecular weight markers (indicated in kDa on the right 
side of panel B).
Figure 4 Purified total soluble mBCO (top panel) and its percent-
age as flavinylated covalent mBCO (bottom panel). Recombinant 
E. coli cells were grown at 37°C, added of 1 mM IPTG at OD600 nm = 1.5-
2, and harvested after 18 hours at the temperature indicated below 
each bar. TB+20G: TB medium in the presence of 20 mL/L of glycerol: 
SB+8G; SB medium in the presence of 8 mL/L of glycerol. Data variabil-
ity is <10%.Volontè et al. BMC Biotechnology 2010, 10:33
http://www.biomedcentral.com/1472-6750/10/33
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protein expression yield as compared to the full length
one when a large (> 1 kb) exogenous cDNA is cloned [11].
In all the constructs, a 6-His tag (encoded by the plasmid)
was added to the C-terminus of the protein. Partial pro-
tein sequences of the protein forms obtained by the dif-
ferent cloning strategies, are shown in Figure 1.
Strain and growth conditions
For protein expression, all plasmids were transferred to
the host BL21(DE3)pLysS E. coli strain. Starter cultures
were prepared using a single colony of E. coli carrying the
recombinant plasmids in LB medium containing kanami-
cin (30 μg/mL final concentration) and chloramphenicol
(34 μg/mL final concentration) under vigorous shaking at
37°C. The following media were used: M9 (6 g/L
Na2HPO4, 3 g/L KH2PO4, 1 g/L NH4Cl, 0.5 g/L NaCl, 0.05
mM CaCl2, 1 mM MgSO4, 4 g/L glucose); Luria-Bertani
(LB, 10 g/L bacto-tryptone, 5 g/L yeast extract, 5 g/L
NaCl); Terrific Broth (TB, 12 g/L bacto-tryptone, 24 g/L
yeast extract, 8 mL/L glycerol, 16 mM KH2PO4 and 54
mM K2HPO4); TB/glucose (12 g/L bacto-tryptone, 24 g/L
yeast extract, 5 g/L glucose, 16 mM KH2PO4 and 54 mM
K2HPO4); Super Broth (SB, 32 g/L bacto-tryptone, 20 g/L
yeast extract, 5 g/L NaCl). When glycerol and/or phos-
phate salts were added to LB or SB media, the same con-
centrations as in TB broth were used, unless otherwise
stated. Baffled (500 mL) Erlenmeyer flasks containing 80
mL of each medium were inoculated with the starter cul-
ture (initial OD600 nm = 0.05) and cells were grown at 37°C
with shaking (180 rpm) until protein expression was
induced.
Enzyme expression and crude extract preparation
Enzyme expression was induced by the addition of differ-
ent IPTG concentrations at different phases of the growth
curve, as indicated in each case. Crude extracts were pre-
pared by French Press lysis or sonication in 50 mM potas-
sium phosphate buffer, pH 7.5, 1 mM pepstatin, 1 mM
phenylmethylsulphonylfluoride (PMSF), 10 μg/mL
DNAse. The insoluble fraction of the lysate was removed
by centrifugation at 39000 × g for 1 hour at 4°C. For
experiments carried out in small volumes (<50 mL),
crude extracts were prepared using the CelLytic™ B
reagent (Sigma-Aldrich), following the manufacturer's
instructions.
Scaling up to 2 L bioreactor
TB medium added with 20 mL/L glycerol was used as
production medium in 2 L working volume P-100 App-
likon glass reactor (height 25 cm, diameter 13 cm)
equipped with a AD1030 Biocontroller and AD1032
motor. Cultivations in fermentor were carried out at
37°C, 500-700 rpm stirring (corresponding to 1.17-1.64
m/s of tip speed) and 2 L/min aeration rate. Foam pro-
duction was controlled by the addition of Hodag anti-
foam through an antifoam sensor. The starter culture was
grown overnight in LB medium and diluted up to an ini-
tial OD600 nm of 0.05. After 1 mM IPTG addition, temper-
ature was shifted down to 21°C and cells were sampled at
different times from induction. Three distinct runs were
carried out.
SDS-PAGE Electrophoresis and Western-blot analysis
Proteins from both soluble and insoluble fractions were
separated by SDS-PAGE, according to [26]. Unstained
polyacrilamide gels were incubated for 1 hour in 10% ace-
tic acid and inspected on an UV-transilluminator. Upon
illumination with UV light, the flavinylated BCO was
visualized because of the FAD fluorescence [27]. For
Western-blot analysis, proteins were transferred electro-
phoretically onto a nitrocellulose membrane and BCO
was detected using anti-His-tag mouse monoclonal anti-
bodies (His-probe, Santa Cruz Biotechnology) and goat
anti-mouse IgG HRP conjugated antibodies (Santa Cruz
Biotechnology). The recognition was then evidenced by a
chemiluminescent method (ECL Plus Western Blotting
Detection System, GE Healthcare).
Determination of enzymatic activity
BCO activity was determined at 25°C using 1 mM choles-
terol in 100 mM potassium phosphate at pH 7.5 in the
presence of 1% propan-2-ol and 1% Thesit® (v/v final con-
centrations) by monitoring H2O2 production using the
horseradish peroxidase assay (4 μg/mL, 0.3 mg/mL o-dia-
nisidine, Δε440 = 13 mM-1cm-1) as previously described
[6,9]. One BCO unit corresponds to the amount of
enzyme that produces one μmol of hydrogen peroxide
per minute, at 25°C.
Purification of recombinant mBCO and determination of 
covalent vs. non-covalent mBCO ratio
Recombinant mBCO containing a C-terminal His-tag
was purified using Ni2+-affinity chromatography (HiTrap
Chelating HP columns equilibrated with 50 mM potas-
sium phosphate, pH 7.5, 1 M NaCl) [10]. Elution of bound
enzyme was performed with a linear gradient of imida-
zole (0-0.5 M) in 50 mM potassium phosphate, pH 7.5,
0.5 M NaCl: recombinant mBCO eluted at about 0.25 M
imidazole. Imidazole was then removed by gel-perme-
ation chromatography on a PD10 column (GE Health-
care) equilibrated with 100 mM potassium phosphate
buffer, pH 7.5, or by extensive dialysis against the same
buffer.
The total amount of purified mBCO was determined
spectrophotometrically using isosbestic points between
absorption spectra of covalent and non-covalent forms of
BCO at 372 nm (ε = 8.97 mM-1cm-1) and at 481 nm (ε =
9.26 mM-1cm-1) [6]. The difference between the concen-Volontè et al. BMC Biotechnology 2010, 10:33
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trations determined at these two wavelengths was in all
cases lower than 5%. The amount of the non-covalent
mBCO was determined following heat denaturation (5
min at 100°C) and centrifugation (10 min at 13000 rpm in
a Heraeus Biofuge, 4°C) to remove the precipitated pro-
tein. Upon denaturation, non-covalent mBCO releases
FAD, that remains in the surnatant: its concentration
(corresponding to the non-covalent mBCO) was deter-
mined spectrophotometrically using ε450 nm = 11.3 mM-
1cm-1.
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